Clinical Research Directory

Inclusion Criteria: * Patient who has been clearly informed of the study and has agreed, with sufficient time for reflection, to participate by signing the study informed consent form. * Male aged ≥ 50 years, * PSA ≤ 15 ng/mL * diagnosis of localized prostate cancer (stage T1 or T2) with a Gleason score of ≤ 7 * Focal, hemiablation or ablation HIFU treatment validated in Multidisciplinary Concerted Meeting * Patient enrolled in Medicare or equivalent plan. * Interpretable preoperative multiparametric MRI performed within 180 days prior to surgery Exclusion Criteria: * an ASA score \>3 * brachytherapy for prostate cancer * Person of full age protected by law (person under guardianship or curatorship). * Contraindication to HIFU treatment as defined in the Focal One instructions for use : - Multiple intraprostatic calcifications inducing, on ultrasound, a shadow cone in the prostate preventing the penetration of ultrasound and therefore the realization of the treatment. * Presence of permanent radioactive implants in the rectal wall. * Presence of an implant (stent, catheter) located less than 1 cm from the treatment area. * Fistula of the urinary tract or rectum. * Anal or rectal fibrosis, anal or rectal stenosis or other abnormalities making insertion of the Focal One® catheter difficult. * Anatomical abnormality of the rectum or rectal mucosa. * Patient with an artificial sphincter, penile prosthesis or intraprostatic implant, such as a stent. * History of inflammatory bowel disease. * Current urogenital infection (infection should be treated prior to HIFU treatment). * Patient allergic to latex with known severe reactionsCounter-indications to anesthesia